Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, and Polyomavirus and related diseases.
Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell Disease
Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell Disease.
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History.
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.
Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease.
One's expectations for normality.
Choosing donors in clinical practice.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507
What causes aplastic anaemia?
Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)
To treat with curative intent or modify disease?
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes
Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population.
Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia.
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.
Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182].
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.